Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.

Drugmaker Sanofi said today it believes the impact from US tariffs to be manageable as it raised its sales growth ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Dupixent (dupilumab) – an IL-4 and IL-13 inhibitor – has dominated the market for biological therapies for atopic dermatitis since it was approved by the FDA in 2017.

DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. DUPIXENT is not used to treat sudden breathing problems.

Dupixent included in list of overseas approved drugs that meet urgent clinical need in China. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the National Medical Products ...